It has become increasingly clear that individual genes do not act in isolation within a cell, but acts in concert with other genes within pathways. In addition, many genes within a pathway are redundant such that many genes can perform a particular function, and conversely a single gene can have many functions depending on its cellular context. High throughput genome wide approaches allow the investigation of the complexity of cell as a whole. The integration of genomics and proteomics with functional analysis will be referred to as systems biology. My lab has utilized these systematic approaches to understand more clearly the biology of high-risk neuroblastoma. Systems biology seeks to integrate high-throughput biological studies to understand how the whole biological systems function. By studying the relationships and interactions between various parts of the biological system (NB in our case), including DNA copy number, methylation patterns, mRNA, miRNA, and protein levels, cell growth, clinical parameters (age, stage and outcome (survival)), it is hoped that eventually this will enable a more complete understanding of NB which will lead to improved survival of patients with minimal long term morbidity. The genome and proteome of a cell is a complex interrelated dynamic system. DNA copy number can impact the mRNA and miRNA expression. mRNA is transcribed into proteins and can contain miRNA sequences, and proteins control transcription by its action on DNA, mRNA and miRNA. In addition, miRNAs control protein and mRNA levels. These global interactions thus control the phenotype of a cancer cell which determines the outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC011002-06
Application #
8763300
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2013
Total Cost
$129,388
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Wei, Jun S; Kuznetsov, Igor B; Zhang, Shile et al. (2018) Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma. Clin Cancer Res :
Xu, Lin; Zheng, Yanbin; Liu, Jing et al. (2018) Integrative Bayesian Analysis Identifies Rhabdomyosarcoma Disease Genes. Cell Rep 24:238-251
Bosse, Kristopher R; Raman, Pichai; Zhu, Zhongyu et al. (2017) Identification of GPC2 as an Oncoprotein and Candidate Immunotherapeutic Target in High-Risk Neuroblastoma. Cancer Cell 32:295-309.e12
Chang, Wendy; Brohl, Andrew S; Patidar, Rajesh et al. (2016) MultiDimensional ClinOmics for Precision Therapy of Children and Adolescent Young Adults with Relapsed and Refractory Cancer: A Report from the Center for Cancer Research. Clin Cancer Res 22:3810-20
Khan, Javed; Helman, Lee J (2016) Precision Therapy for Pediatric Cancers. JAMA Oncol :
Zhang, Shile; Wei, Jun S; Li, Samuel Q et al. (2016) MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma. Cancer Lett 371:214-24
Oldridge, Derek A; Wood, Andrew C; Weichert-Leahey, Nina et al. (2015) Genetic predisposition to neuroblastoma mediated by a LMO1 super-enhancer polymorphism. Nature 528:418-21
Chen, Justin; Hackett, Christopher S; Zhang, Shile et al. (2015) The genetics of splicing in neuroblastoma. Cancer Discov 5:380-95
McKinnon, Timothy; Venier, Rosemarie; Dickson, Brendan C et al. (2015) Kras activation in p53-deficient myoblasts results in high-grade sarcoma formation with impaired myogenic differentiation. Oncotarget 6:14220-32
Shern, Jack F; Yohe, Marielle E; Khan, Javed (2015) Pediatric Rhabdomyosarcoma. Crit Rev Oncog 20:227-43

Showing the most recent 10 out of 34 publications